Upregulation of receptor tyrosine kinase-like orphan receptor 2 in idiopathic pulmonary fibrosis

Ji-Hye Son; Jong-Uk Lee; Susie Chin; Eun-Suk Go; Jai-Seong Park; Hwa-Kyun Shin; Hun Soo Chang; Jong-Sook Park; Choon-Sik Park

doi:10.3904/kjim.2019.270

Korean J Intern Med > Volume 36(4); 2021 > Article

Son, Lee, Chin, Go, Park, Shin, Chang, Park, and Park: Upregulation of receptor tyrosine kinase-like orphan receptor 2 in idiopathic pulmonary fibrosis

Original Article

Pulmonology

Korean J Intern Med 2021;36(4):914-923.

Published online: September 21, 2020

DOI: https://doi.org/10.3904/kjim.2019.270

Upregulation of receptor tyrosine kinase-like orphan receptor 2 in idiopathic pulmonary fibrosis

Ji-Hye Son^1,^*, Jong-Uk Lee^2,^*, Susie Chin³, Eun-Suk Go⁴, Jai-Seong Park⁵, Hwa-Kyun Shin⁶, Hun Soo Chang¹, Jong-Sook Park²

, Choon-Sik Park²

¹Department of Interdisciplinary Program in Biomedical Science Major, Graduate School, Soonchunhyang University, Asan, Korea

²Genome Research Center and Division of Allergy and Respiratory Medicine, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea

³Department of Pathology, Soonchunhyang University Bucheon Hospital, Bucheon, Korea

⁴Department of Pathology, Soonchunhyang University College of Medicine, Asan, Korea

⁵Department of Radiology, Soonchunhyang University College of Medicine, Asan, Korea

⁶Department of Thoracic Surgery, Soonchunhyang University College of Medicine, Asan, Korea

Correspondence to Jong-Sook Park, M.D. Division of Allergy and Respiratory Medicine, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, 170, Jomaru-ro, Wonmi-gu, Bucheon 14584, Korea Tel: +82-32-621-5105 Fax: +82-32-621-5023 E-mail: newstart1221@naver.com

^*These authors contributed equally to this work.

Received February 5, 2019 Revised September 4, 2019 Accepted December 18, 2019

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background/Aims

Receptor tyrosine kinase-like orphan receptor 2 (ROR2) is a major regulator of Wnt signaling, which is involved in fibroblast dysfunction. Because its role has not been evaluated in idiopathic pulmonary fibrosis (IPF), we examined the clinical implications of ROR2 expression.

Methods

ROR2 mRNA expression was measured using reverse transcription polymerase chain reaction in lung tissue-derived fibroblasts from IPF patients (n = 14) and from controls (n = 10). ROR2 protein was measured using enzyme-linked immunosorbent assay in primary fibroblasts from IPF patients (n = 14) and controls (n = 10), and in bronchoalveolar lavage (BAL) fluids obtained from normal controls (NC; n = 30). IPF patients (n = 84), and other patients with interstitial lung diseases, including nonspecific interstitial pneumonia (NSIP; n = 10), hypersensitivity pneumonitis (HP; n = 10), and sarcoidosis (n = 10).

Results

ROR2 mRNA and protein levels were significantly higher in IPF fibroblasts than in controls (p = 0.003, p = 0.0017, respectively). ROR2 protein levels in BAL fluids from patients with IPF were significantly higher than in those from NC (p < 0.001), and from patients with NSIP (p = 0.006), HP (p = 0.004), or sarcoidosis (p = 0.004). Receiver operating characteristic curves showed a clear difference between IPF and NC in ROR2 protein level (area under the curve, 0.890; confidence interval, 0.829 to 0.950; p < 0.001). ROR2 protein levels were significantly higher in GAP stage III than in GAP stages I and II (p = 0.016).

Conclusions

ROR2 may be related to the development of IPF, and its protein level may be a useful and severity-dependent candidate marker for IPF.

Keywords: Idiopathic pulmonary fibrosis; Receptor tyrosine kinase-like orphan receptors; Bronchoalveolar lavage fluid; Differential diagnosis

INTRODUCTION

Idiopathic pulmonary fibrosis (IPF) comprises a group of lung diseases induced by both genetic and epigenetic factors [1]. Among the genetic factors, MUC5B, SFTPC, SFTPA2, RTEL1, TERT, and hTR have been implicated in the development of IPF [2], and global gene expression studies have identified several novel genes expressed in IPF lung tissues [3-6]. Complex interactions among these genes may determine the development and disease progression of IPF [7,8]. Recently, we demonstrated that 178 genes were differentially expressed in IPF lung tissue-derived fibroblasts [9]. Of these, mRNA expression of receptor tyrosine kinase-like orphan receptor 2 (ROR2) was more than 20-fold higher in IPF fibroblasts than in cells from control lungs.

WNT5A is a member of the Wnt family of secreted glycoproteins, which have crucial roles in many cellular activities, including proliferation, differentiation, migration, cell polarity, and cell adhesion [10]. WNT5A is an important regulator of fibroblast proliferation with resistance to apoptosis [11], a characteristic seen in IPF. ROR2 acts as a receptor or co-receptor for WNT5A, and mediates non-canonical Wnt signaling [12]. In the submandibular gland, ROR2-mediated signaling is activated in response to tissue damage, and is associated with the progression of fibrosis [13]. However, its expression has not been evaluated in patients with IPF. Thus, in the present study, we evaluated the relationship between ROR2 expression and clinical characteristics of IPF, assaying ROR2 mRNA and protein levels in fibroblasts and bronchoalveolar lavage (BAL) fluids from normal controls (NC), patients with IPF, and patients with other interstitial lung diseases (ILDs).

METHODS

Study subjects

Primary lung fibroblasts and BAL fluids from patients with diffuse ILDs were obtained from the biobank of Soonchunhyang University Hospital, Bucheon, Korea, after approval of the study protocol by the Ethics Committee of Soonchunhyang University Hospital (IRB No: SCHCA-IRB-2018–10–034 and 201910-BR-058). NCs BAL fluids were obtained from the general population and from hospital personnel, after approval by the hospital Ethics Committee (IRB No: SCHBC 2015–08–025–005). Informed written consent for study participation and sample donation was obtained from each subject. The diagnostic criteria for IPF, hypersensitivity pneumonitis (HP), nonspecific interstitial pneumonia (NSIP), and sarcoidosis were based on international consensus statements [14-22]. The clinical and laboratory data are summarized in the Supplementary material.

Fibroblast culture

Primary lung fibroblasts were cultured from surgical lung specimens of 14 IPF patients and 10 control subjects who underwent surgery for stage I or II lung cancer, as described previously [9]; their clinical characteristics are summarized in Supplementary Table 1 [9,23]. Briefly, lung specimens were finely minced and placed into 150 cm2 cell culture flasks with tissue culture media (TCM) consisting of DMEM (Lonza Inc., Walkersville, MD, USA), 10% fetal bovine serum (Thermo Fisher Scientific Inc., Rockford, IL, USA), 2 mmol/L glutamine, and 1% penicillin-streptomycin-amphotericin (Lonza). Cells were maintained at 37°C in a 5% CO₂ incubator and serially subcultured until the fourth passage to yield a morphologically homogeneous population of adherent fibroblasts staining positive for α-smooth muscle actin (SMA; Abcam, Cambridge, MA, USA). Then the cells were stored at −170°C. Fifth-passage fibroblasts (1 × 10⁶) were seeded in 1 mL TCM in 10 cm2 dishes and cultured for 48 hours. After reaching 90% confluence, fibroblasts were washed twice with PBS (Thermo Fisher) and total RNA was extracted using TRI reagent (Ambion, Carlsbad, CA, USA).

Detection of ROR2 mRNA in primary fibroblasts using reverse transcription PCR

Extracted RNA was treated using the Turbo DNA-Free kit (AM1907; Invitrogen, Camarillo, CA, USA). The resulting total RNA (1 μg) was suspended in diethylpyrocarbonate-treated water with 0.5 μg 10 mM dNTPs and oligodeoxythymidine, heated at 65°C for 5 minutes, and then cooled on ice. PCR amplification was performed for 30 cycles (5 minutes at 95°C, 30 seconds at 95°C, 30 seconds at 58°C, and 30 seconds at 72°C) with a final extension at 72°C for 7 minutes. The following primer sequences were used: ROR2, (sense) 5′-TACGCATGGAACTGTGTGAC-3′ and (antisense) 5′-GAGGGGCATTTCCATGTCTTG-3′; β-actin, (sense) 5′-GGACTTCGAGCAAGAGATGG-3′ and (antisense) 5′-AGCACTGTGTTGGCGTACAG-3′. The PCR products were separated on a 1.0% agarose gel containing ethidium bromide in Tris-borate ethylenediaminetetraacetic acid (EDTA) buffer at 100 V for 40 minutes and visualized under ultraviolet light. ROR2 band intensities were normalized to those of β-actin.

Measurement of ROR2 protein in fibroblasts and BAL fluid using enzyme-linked immunosorbent assay

Primary lung fibroblast cells lysed in RIPA buffer (Sigma-Aldrich, St. Louis, MO, USA) with protease-inhibitor (Thermo Fisher) were analyzed using an ROR2 ELISA kit (MyBioSource, San Diego, CA, USA), and protein concentrations were measured using a BCA kit (Thermo Fisher). BAL was collected either from lung segments exhibiting the greatest disease involvement on high-resolution computed tomography (HRCT) in the absence of immunosuppressive therapy, or from the right middle lobe of NC, as described previously [24,25]. Total cell counts were performed using a hemocytometer. Cells were collected by centrifugation (500 × g, 5 minutes), and the supernatants were stored at –80°C. Differential cell counts were performed on 500 cells from BAL fluids, on slides prepared using a cytocentrifuge and Diff-Quik staining, and ROR2 protein levels were measured using an ROR2 ELISA kit according to the manufacturer’s recommendations. The lower limit of detection was 0.25 ng/mL, and values below this limit were set to 0. The inter- and intra-assay coefficients of variation were less than 15%.

GAP stage

Total GAP scores were calculated using the method of Ley et al. [26]. The following four clinical variables were examined to determine the GAP score: sex (0 points for female, 1 point for male), age (0–2 points), forced vital capacity (FVC)% (0–2 points), and diffusing capacity of lung for carbon monoxide (DLCO)% (0–3 points). Patients were divided into eight groups, according to their GAP scores: group 0 (n = 4), group 1 (n = 11), group 2 (n = 20), group 3 (n = 12), group 4 (n = 15), group 5 (n = 11), group 6 (n = 7), and group 7 (n = 4). DLCO was not measured in eight subjects with IPF and thus was excluded from the determinations of GAP scores. GAP scores divided the patients into three stages: GAP stages I (groups 0–3, n = 47), II (groups 4–5, n = 26), and III (groups 6–8, n = 11) (Supplementary Table 2).

Statistical analyses

Data were analyzed using IBM SPSS version 20.0. (IBM Corp., Armonk, NY, USA). The normality of data distribution was tested using the Shapiro–Wilk test. Categorical values were compared using chi-square test and Fisher exact tests. Comparisons were performed using the Kruskal-Wallis test and a post hoc analyses; a Mann-Whitney U test was conducted for comparisons between two groups. Correlations between ROR2 level and other parameters were analyzed using Spearman’s correlation coefficient. Receiver operator characteristic (ROC) analyses were performed to define cut-off values of the scores. The best cut-off values were calculated using the highest Youden’s index. Comparison between different areas under the curve (AUC) was performed using the Z statistic calculation, according to the method of DeLong et al. [27], using MedCalc Statistical Software version 12.2.1.0 (MedCalc Software bvba, Ostend, Belgium). Data are presented as medians with 25% and 75% quartiles for variables with a skewed distribution, or as means ± standard errors of the mean for variables with a normal distribution. Values for p < 0.05 were considered statistically significant.

RESULTS

Clinical characteristics of study groups

Primary fibroblasts were obtained from 14 IPF patients and 10 NC who underwent lung surgery. Clinical information and laboratory data for these subjects have been summarized in a previous study and in Supplementary Table 1 [9]. BAL fluid samples were obtained from patients with IPF (n = 84), NSIP (n = 10), HP (n = 10), and sarcoidosis (n = 10); clinical characteristics of these patients are summarized in Table 1. Patients with IPF had significantly lower FVC and forced expiratory values (FEV1) compared to NC (p < 0.05).

ROR2 mRNA in primary fibroblasts and protein levels in fibroblasts and BAL fluids

The ROR2 mRNA and protein levels in fibroblasts were two-fold higher in the IPF patients than in controls, by reverse transcription PCR and ELISA (p = 0.003 and p = 0.0017, respectively) (Fig. 1). In BAL fluids, there were significant differences in ROR2 protein levels among the NC (0.014 ng/mL [range, 0 to 0.053 ng/mL]), IPF (1.934 ng/mL [range, 0.347 to 9.252 ng/mL]), NSIP (0 ng/mL [range, 0 to 1.866 ng/mL]), HP (0.127 ng/mL [range, 0 to 0.793 ng/mL]), and sarcoidosis (0 ng/mL [0 to 1.866 ng/mL]) groups (Fig. 2A). ROR2 levels were significantly higher in IPF patients than in NC (p < 0.001), HP patients (p = 0.004), NSIP patients (p = 0.006), and sarcoidosis patients (p = 0.004). The ROC curve showed a clear difference between IPF patients and NC (AUC, 0.890; 95% confidence interval [CI], 0.82 to 0.950) (Fig. 2B) and between IPF patients and those with other ILDs (n = 30; AUC, 0.718; 95% CI, 0.660 to 0.866) (Fig. 2C). A cut-off level of 0.305 ng/mL gave 93.3% specificity and 76.2% sensitivity for distinguishing between NC and IPF patients. A cut-off level of 0.082 ng/mL exhibited 53.3% specificity and 88.1% sensitivity for distinguishing between IPF and other ILDs. There were no differences in plasma ROR2 levels between 37 NC and 90 IPF patients (p = 0.105) (Supplementary ig. 1A), and no correlation between ROR2 concentrations in plasma and those in BAL fluids of 60 IPF patients (p = 0.923) (Supplementary Fig. 1B).

ROR2 protein levels and clinical characteristics

Patients were divided into eight groups according to their GAP score: group 0 (n = 4), group 1 (n = 11), group 2 (n = 20), group 3 (n = 12), group 4 (n = 15), group 5 (n = 11), group 6 (n = 7), and group 7 (n = 4) (Supplementary Table 1). There were significant differences in ROR2 protein levels by GAP stage (stage I vs. II vs. III: 1.718 ng/mL [range, 0.193 to 8.613 ng/mL] vs. 1.015 ng/mL [range, 0.322 to 4.674 ng/mL] vs. 10.547 ng/mL [range, 3.989 to 11.593 ng/mL]; p = 0.016) (Fig. 3A and Supplementary Table 3). There were no differences in ROR2 protein levels with smoking status (NS vs. ES vs. SM: 1.627 ng/mL [range, 0.264 to 7.034 ng/mL] vs. 1.593 ng/mL [range, 0.379 to 8.954 ng/mL] vs. 3.347 ng/mL [range, 0.788 to 9.457 ng/mL]) (Fig. 3B), or sex (males vs. females: 1.718 ng/mL [range, 0.45 to 9.544 ng/mL] vs. 2.762 ng/mL [range, 0.24 to 8.006 ng/mL]) (Fig. 3C). ROR2 protein level was not correlated with differential cell counts in BAL fluid, initial FVC and DLCO, or changes in those parameters during follow-up (Supplementary Table 4).

Correlation analyses between ROR2 and genes associated with Wnt signaling

Correlation analyses were performed on expression of the ROR2 gene with genes related to the Wnt signaling pathway in IPF fibroblasts (p < 0.05) (Fig. 4 and Supplementary Table 5). Among the 15,020 genes expressed by fibroblasts [9], 22 genes associated with Wnt pathways were significantly correlated with ROR2 gene expression. This finding indicates that the ROR2 gene may have a synergistic regulatory effect on lung fibrosis by acting with other Wnt signaling genes.

DISCUSSION

We demonstrated that ROR2 gene and protein expression were significantly increased in the primary fibroblasts of IPF patients compared to controls, and that ROR2 protein in IPF BAL fluids was also significantly elevated, relative both to controls and to patients with other ILDs. In addition, IPF was differentially diagnosed from NC and from other ILDs at ROC cut-off levels for ROR2 of 0.305 ng/mL and 0.082 ng/mL, respectively. Clinically, ROR2 protein levels were significantly increased in more severe manifestations of IPF, including GAP stage III. To the best of our knowledge, this is the first evidence suggesting that ROR2 expression is related to the development and severity of IPF and that ROR2 protein level may be a surrogate biomarker for differentially diagnosing IPF from other ILDs. MMP-1, MMP-7 [28], CCL8 [9], CCL18 [29], YKL-40 [30], SPA, SP-D [31], and KL-6 [32] have been proposed as biomarkers of IPF. In a previous study, plasma MMP-1 and MMP-7 levels were significantly higher in IPF patients than in those with other lung diseases, such as chronic obstructive pulmonary disease and sarcoidosis, with a sensitivity of 96.3% and a specificity of 87.2% for the differential diagnosis of IPF from HP [28]. In a previous study, we reported 178 differentially expressed genes in fibroblasts derived from IPF lungs [9]. Among the top 15 genes, ROR2 expression was >20-fold higher in IPF fibroblasts. In that study, we performed analyses using GEO datasets (Sridhr’s study using primary fibroblasts [n = 1,813, 4 controls and 10 IPF subjects; GSE44723] and Ronzani’s study [n = 3, 5 controls and 5 IPF subjects; GES45686]). Compared to the 178 genes identified in our study, only 9 genes (MOXD1, PITX1, POSTN, TMEM51, CDC42EP3, UBE2K, ALDH3A2, NBEAL2, and IGFBP2) overlapped, and ROR2 was not among them. This may be due to biological differences between the primary fibroblasts used in our study and uncultured cells isolated from IPF lungs.

ROR2 is a transmembrane protein with normal expression in the developing heart, brain, and lungs [33,34]. It is localized mainly near the plasma membrane [35], and was easily detected in BAL fluids in our study. In addition, ROR2 level was not correlated with the cellular profile of BAL fluid or with lung function profile or age. In post hoc analyses, there were no significant differences in ROR2 levels with sex or smoking status (Fig. 3). The potential role of ROR2 in Wnt signaling has recently been revealed. Wnt signaling is mediated through both beta-catenin-dependent and independent pathways [36]. Multiple receptors, including Frizzled (Fzd), Lrps, ROR2, and Ryk, are involved in Wnt signaling. Wnt ligands interact with the Fzd family of seven-span transmembrane receptor molecules and co-receptors of the low-density lipoprotein receptor-related protein (Lrp) family [37]. The cysteine-rich domains (CRDs) of ROR2 interact with Wnt ligands and the CRDs of Fzd2 in the N-terminal extracellular region [38]. ROR2 acts as a receptor or co-receptor for WNT5A, and mediates non-canonical Wnt signaling, including the inhibitory effects of WNT5A on WNT3A-mediated activation of the canonical Wnt pathway [12,39]. WNT5A is a key regulator of epithelial-mesenchymal interactions during lung development and maturation [40], and is an important regulator of fibroblast proliferation with resistance to apoptosis [11,41], both of which are characteristic of IPF. WNT5A signaling is also involved in producing pro-inflammatory cytokines, such as interleukin (IL)-12 and IL-6 [42,43]. Thus, increased levels of ROR2 may modulate Wnt/β-catenin signaling, leading to increased numbers of fibroblasts via inhibition of apoptosis.

One limitation of our study was the small number of subjects, particularly those with other ILDs, including NSIP, HP, and sarcoidosis. In addition, long-term follow-up will be necessary to fully address the clinical implications of ROR2, particularly the survival rate of IPF. Furthermore, validation studies using other cohorts are required to improve the diagnostic utility of ROR2.

In conclusions, ROR2 mRNA and protein levels were significantly higher in IPF fibroblasts, and ROR2 protein was significantly elevated in the BAL fluid of patients with IPF, compared to NC and those with other ILDs, including HP, NSIP, and sarcoidosis. Cut-off ROR2 levels of 0.305 and 0.082 ng/mL offered good accuracy with high specificity and sensitivity for differentiating IPF from NC and from other ILDs. Our data suggest that ROR2 has potential for use as a surrogate diagnostic marker.

KEY MESSAGE

1. Receptor tyrosine kinase-like orphan receptor 2 (ROR2) level was significantly higher in bronchoalveolar lavage f luid of patients with idiopathic pulmonary fibrosis (IPF).

2. ROR2 offered good diagnostic accuracy with high specificity and sensitivity for differentiating IPF from normal control.

3. ROR2 levels were significantly higher in GAP stage III than in GAP stages I and II.

Conflict of Interest

No potential conflict of interest relevant to this article was reported.

Acknowledgments

This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2020R1I1A1A01067088). And a Soonchunhynag University grant to Jong Sook Park. The samples were generously provided by Soonchunhyang University, Bucheon Hospital Biobank, a member of the National Biobank of Korea, supported by the Ministry of Health, Welfare, and Family Affairs, Republic of Korea.

Supplementary Material

SUPPLEMENTARY MATERIAL

kjim-2019-270-suppl1.pdf

Supplementary Table 1.

Clinical characteristics of the study subjects providing fibroblasts for culture

kjim-2019-270-suppl2.pdf

Supplementary Table 2.

Distribution of subjects with IPF according to GAP points

kjim-2019-270-suppl3.pdf

Supplemental Table 3.

Clinical characteristics of GAP stage-sorted IPF patients

kjim-2019-270-suppl4.pdf

Supplemental Table 4.

Correlation of ROR2 levels with BAL fluid cell and lung function profiles in IPF

kjim-2019-270-suppl5.pdf

Supplemental Table 5.

Correlation of ROR2 protein concentration with WNT pathway-related gene expression in IPF patients (p < 0.05)

kjim-2019-270-suppl6.pdf

Supplementary Figure 1.

Receptor tyrosine kinase-like orphan receptor 2 (ROR2) concentrations in plasma and its correlation with ROR2 levels in bronchoalveolar lavage fluids (BALFs). (A) ROR2 concentrations in plasma from normal controls (n = 37) and idiopathic pulmonary fibrosis (IPF) subjects (n = 90). (B) Correlation of paired samples between plasma and BALFs from IPF subjects (n = 49). The data are presented as median values with 25% and 75% quartiles.

kjim-2019-270-suppl7.pdf

Figure 1.

Receptor tyrosine kinase-like orphan receptor 2 (ROR2) mRNA and protein levels in lung fibroblasts from 14 idiopathic pulmonary fibrosis (IPF) patients and 10 controls. (A) Reverse transcription PCR and (B) densitometric analyses of ROR2 band intensities after normalization to those of β-actin. (C) ROR2 protein in cell lysates. The data are presented as medians with 25% and 75% quartiles.

Figure 2.

Receptor tyrosine kinase-like orphan receptor 2 (ROR2) protein concentrations in bronchoalveolar lavage (BAL) fluids and receiver operating characteristic (ROC) analyses among study groups. (A) ROR2 protein was detected in 15 of 30 normal controls (NC), 78 of 84 idiopathic pulmonary fibrosis (IPF) patients, 4 of 10 hypersensitivity pneumonitis (HP) patients, 4 of 10 nonspecific interstitial pneumonia (NSIP) patients, and 0 of 10 sarcoidosis patients. The data are presented as median values with 25% and 75% quartiles. (B) ROC curve of ROR2 protein levels in IPF patients and NC. A cut-off value of 0.305 ng/mL had an area under the curve (AUC) of 0.890, a specificity of 93.3%, and a sensitivity of 76.2% for differentiating IPF patients from NC. (C) ROC curve of the ROR2 protein level in patients with IPF and those with other interstitial lung diseases (ILDs). A cut-off value of 0.082 ng/mL had an AUC of 0.763, a specificity of 53.3%, and a sensitivity of 88.1% for differentiating IPF patients from those with other ILDs.

Figure 3.

Comparisons of receptor tyrosine kinase-like orphan receptor 2 (ROR2) protein concentrations in bronchoalveolar lavage fluids from idiopathic pulmonary fibrosis patients according to (A) GAP stage, (B) smoking status, and (C) sex. NS, never-smoker; ES, ex-smoker; SM, smoker.

Figure 4.

Correlation of idiopathic pulmonary fibrosis fibroblast gene expression between receptor tyrosine kinase-like orphan receptor 2 (ROR2) and Wnt signaling pathway genes. LRP5/6, low density lipoprotein receptor-related protein 5/6; Fz, frizzled; SENP2, sentrin-specific protease 2; Dvl, dishevelled segment polarity protein; GSK3β, glycogen synthase kinase 3 beta; CCND, cyclin D1; FOSL1, FOS like 1, AP-1 transcription factor subunit; TCF, T-cell factor; LEF, lymphoid enhancer factor; PRIKCLE, prickle planar cell polarity protein; DAAM1, disheveled-associated activator of morphogenesis 1; RhoA, Ras homolog family member A; ROCK, Rho associated coiled-coil containing protein kinase; Rac, Rac family small GTPase 1; MAPK, mitogen-activated protein kinase; Dsh, dishevelled; PDE, phosphodiesterase; PLC, phospholipase C gamma; PRKC, serine/threonine-protein kinase PrkC; PPP3C, protein phosphatase 3 catalytic subunit; CAMK2, Ca²⁺/calmodulin-dependent protein kinase II.

Table 1.

Clinical characteristics of the study subjects

Item	Normal control	IPF	NSIP	HP	Sarcoidosis
No.	30	84	10	10	10
Age, yr	55 (35–72)	63.41 (32–85)	54.18 (39–70)^a	44.58 (27–63)^a	41.90 (27–68)^a
Sex (male/female)	17/13	51/33	3/7	4/6	6/4
Smoking (NS/ES/SM/ND)	ND	37/24/22/1	5/2/1/2	6/1/2/1	5/2/3/0
Follow-up duration, yr	ND	4.90 (2.35–6.40)	ND	ND	ND
FVC, % pred.	115.00 (106.25–132.25)	75.50 (65.00–84.75)^b	61.00 (51.75–81.50)^b	63.50 (55.50–78.50)^b	86.50 (72.50–99.25)^a,b
FEV1, % pred.	104.00 (88.48–121.25)	89.50 (78.00–100)^b	68.50 (56.75–93.50)^a,b	73.00 (60.00–90.00)^a,b	98.00 (80.50–106.25)
DLCO, % pred.	ND	63.00 (46.0–71.75)	59.50 (51.00–71.25)	67.00 (58.00–75.00)	89.50 (87.25–100)^a
BAL total cell count, ×10⁴/mL	4.05 ± 0.51	18.62 ± 30.06^b	9.30 ± 3.53^b	10.28 ± 5.94^b	12.04 ± 8.07^b
Macrophages, %	94.95 ± 9.12	56.01 ± 24.98^b	67.91 ± 27.32^b	58.93 ± 29.52^b	71.23 ± 14.76^b
Neutrophils, %	3.36 ± 4.92	26.07 ± 21.31^b	13.63 ± 7.61^b	22.43 ± 19.27^b	4.73 ± 7.52^b
Eosinophils, %	0.55 ± 1.02	3.26 ± 8.02^b	2.65 ± 1.29^b	2.93 ± 4.51^b	1.16 ± 0.77^b
Lymphocytes, %	0.43 ± 4.52	4.02 ± 4.71^b	15.81 ± 3.13^b	15.72 ± 5.78^b	22.87 ± 4.81^b

Values are presented as median (interquartile range) or mean ± SD. Patient characteristics and pulmonary function tests were examined using Kruskal-Wallis analysis of variance among the controls, IPF, NSIP, HP, and sarcoidosis groups, and Mann-Whitney U for post hoc tests; Mann-Whitney U tests were conducted for comparisons between two groups. BAL cell numbers were compared using Kruskal-Wallis analysis of variance among the five groups and Tukey’s honest significant difference test was used as a post hoc test.

IPF, idiopathic pulmonary fibrosis; NSIP, nonspecific interstitial fibrosis; HP, hypersensitivity pneumonitis; NS/ES/SM/ND, never-smokers/ex-smokers/smokers/not-determined; ND, not done; FVC, forced vital capacity; FEV, forced expiratory value; DLCO, diffusing capacity of the lungs for carbon monoxide; BAL, bronchoalveolar lavage.

^a Compared to IPF, p < 0.05.

^b Compared to normal control, p < 0.05.

REFERENCES

1. Wahidi M, Schwartz D, Raghu G. Genetics of familial pulmonary fibrosis and other variants. In: Lynch JP, ed. Idiopathic Pulmonary Fibrosis. Raton (FL): CRC Press, 2003;31–54.

2. Schwartz DA. Idiopathic pulmonary fibrosis is a complex genetic disorder. Trans Am Clin Climatol Assoc 2016;127:34–45.

3. Boon K, Bailey NW, Yang J, et al. Molecular phenotypes distinguish patients with relatively stable from progressive idiopathic pulmonary fibrosis (IPF). PLoS One 2009;4:e5134.

4. Konishi K, Gibson KF, Lindell KO, et al. Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009;180:167–175.

5. Selman M, Pardo A, Barrera L, et al. Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis. Am J Respir Crit Care Med 2006;173:188–198.

6. Zuo F, Kaminski N, Eugui E, et al. Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc Natl Acad Sci U S A 2002;99:6292–6297.

7. Kim DS, Collard HR, King TE Jr. Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc 2006;3:285–292.

8. Wynn TA. Integrating mechanisms of pulmonary fibrosis. J Exp Med 2011;208:1339–1350.

9. Lee JU, Cheong HS, Shim EY, et al. Gene profile of fibroblasts identify relation of CCL8 with idiopathic pulmonary fibrosis. Respir Res 2017;18:3.

10. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004;20:781–810.

11. Vuga LJ, Ben-Yehudah A, Kovkarova-Naumovski E, et al. WNT5A is a regulator of fibroblast proliferation and resistance to apoptosis. Am J Respir Cell Mol Biol 2009;41:583–589.

12. Oishi I, Suzuki H, Onishi N, et al. The receptor tyrosine kinase Ror2 is involved in non-canonical Wnt5a/JNK signalling pathway. Genes Cells 2003;8:645–654.

13. Takahashi D, Suzuki H, Kakei Y, et al. Expression of Ror2 associated with fibrosis of the submandibular gland. Cell Struct Funct 2017;42:159–167.

14. American Thoracic Society (ATS); the European Respiratory Society (ERS). American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 2000;161(2 Pt 1):646–664.

15. Selman M, Pardo A, King TE Jr. Hypersensitivity pneumonitis: insights in diagnosis and pathobiology. Am J Respir Crit Care Med 2012;186:314–324.

16. Parrish S, Turner JF. Diagnosis of sarcoidosis. Dis Mon 2009;55:693–703.

17. Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med 2011;183:573–581.

18. Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013;188:733–748.

19. American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002;165:277–304.

20. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788–824.

21. Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 2018;198:e44–e68.

22. Katzenstein AL, Fiorelli RF. Nonspecific interstitial pneumonia/fibrosis. Histologic features and clinical significance. Am J Surg Pathol 1994;18:136–147.

23. Lee JU, Son JH, Shim EY, et al. Global DNA methylation pattern of fibroblasts in idiopathic pulmonary fibrosis. DNA Cell Biol 2019;38:905–914.

24. Kim TH, Lee YH, Kim KH, et al. Role of lung apolipoprotein A-I in idiopathic pulmonary fibrosis: antiinflammatory and antifibrotic effect on experimental lung injury and Fibrosis. Am J Respir Crit Care Med 2010;182:633–642.

25. Park SW, Ahn MH, Jang HK, et al. Interleukin-13 and its receptors in idiopathic interstitial pneumonia: clinical implications for lung function. J Korean Med Sci 2009;24:614–620.

26. Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012;156:684–691.

27. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837–845.

28. Rosas IO, Richards TJ, Konishi K, et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med 2008;5:e93.

29. Cai M, Bonella F, He X, et al. CCL18 in serum, BAL fluid and alveolar macrophage culture supernatant in interstitial lung diseases. Respir Med 2013;107:1444–1452.

30. Korthagen NM, van Moorsel CH, Barlo NP, et al. Serum and BALF YKL-40 levels are predictors of survival in idiopathic pulmonary fibrosis. Respir Med 2011;105:106–113.

31. Wang K, Ju Q, Cao J, Tang W, Zhang J. Impact of serum SP-A and SP-D levels on comparison and prognosis of idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Medicine (Baltimore) 2017;96:e7083.

32. Hamai K, Iwamoto H, Ishikawa N, et al. Comparative study of circulating MMP-7, CCL18, KL-6, SP-A, and SP-D as disease markers of idiopathic pulmonary fibrosis. Dis Markers 2016;2016:4759040.

33. Yoda A, Oishi I, Minami Y. Expression and function of the Ror-family receptor tyrosine kinases during development: lessons from genetic analyses of nematodes, mice, and humans. J Recept Signal Transduct Res 2003;23:1–15.

34. Schwabe GC, Trepczik B, Suring K, et al. Ror2 knockout mouse as a model for the developmental pathology of autosomal recessive Robinow syndrome. Dev Dyn 2004;229:400–410.

35. Masiakowski P, Carroll RD. A novel family of cell surface receptors with tyrosine kinase-like domain. J Biol Chem 1992;267:26181–26190.

36. Li C, Chen H, Hu L, et al. Ror2 modulates the canonical Wnt signaling in lung epithelial cells through cooperation with Fzd2. BMC Mol Biol 2008;9:11.

37. Yamaguchi TP, Bradley A, McMahon AP, Jones S. A Wnt5a pathway underlies outgrowth of multiple structures in the vertebrate embryo. Development 1999;126:1211–1223.

38. Liang H, Chen Q, Coles AH, et al. Wnt5a inhibits B cell proliferation and functions as a tumor suppressor in hematopoietic tissue. Cancer Cell 2003;4:349–360.

39. Sato A, Yamamoto H, Sakane H, Koyama H, Kikuchi A. Wnt5a regulates distinct signalling pathways by binding to Frizzled2. EMBO J 2010;29:41–54.

40. Pereira C, Schaer DJ, Bachli EB, Kurrer MO, Schoedon G. Wnt5A/CaMKII signaling contributes to the inflammatory response of macrophages and is a target for the antiinflammatory action of activated protein C and interleukin-10. Arterioscler Thromb Vasc Biol 2008;28:504–510.

41. Mikels A, Minami Y, Nusse R. Ror2 receptor requires tyrosine kinase activity to mediate Wnt5A signaling. J Biol Chem 2009;284:30167–30176.

42. Blumenthal A, Ehlers S, Lauber J, et al. The Wingless homolog WNT5A and its receptor Frizzled-5 regulate inflammatory responses of human mononuclear cells induced by microbial stimulation. Blood 2006;108:965–973.

43. Naskar D, Maiti G, Chakraborty A, Roy A, Chattopadhyay D, Sen M. Wnt5a-Rac1-NF-κB homeostatic circuitry sustains innate immune functions in macrophages. J Immunol 2014;192:4386–4397.